CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech company, achieved a major milestone when it earned approval for the ...
Pairwise, a global innovator in agriculture, today announced a licensing agreement with Ball® Horticultural Company (Ball), one of the world’s leading ornamental plant breeders and distributors, ...
CRISPR Therapeutics stock snapshot and recent performance CRISPR Therapeutics (CRSP) has drawn investor attention after its ...
Zacks Investment Research on MSN
Investors heavily search CRISPR Therapeutics AG (CRSP): Here is what you need to know
CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
Genome‑wide CRISPR screens in primary human T cells reveal human genes that promote or block HIV infection, uncovering potent ...
There are plenty of reasons, though, to be bullish on the stock, not the least of which is its improved cash position. The ...
Live Science on MSN
$3 million prize goes to duo whose research led to first sickle cell CRISPR therapy
Dr. Swee Lay Thein and Dr. Stuart Orkin won the $3 million Breakthrough Prize in Life Sciences for their work toward a ...
Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of ...
Morning Overview on MSN
Harvard team uses CRISPR to silence extra chromosome 21 in lab
A research team led by geneticist Jeannie Lee at Harvard Medical School, cell biologist Jeanne Lawrence at UMass Chan Medical ...
Researchers have developed a modified CRISPR gene-editing tool with potential to silence the extra chromosome causing Down ...
A research team has discovered an enhanced CRISPR gene-editing system that could enable targeted delivery inside the human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results